Antinociceptive activity in Swiss albino mouse assessed as inhibition of acetic acid-induced abdominal constriction at 10 mg/kg, po administered 30 mins prior to testing measured for 10 mins starting 5 mins after acetic acid injection relative to control
Antinociceptive activity in Swiss albino mouse assessed as inhibition of acetic acid-induced abdominal constriction at 40 mg/kg, po administered 30 mins prior to testing measured for 10 mins starting 5 mins after acetic acid injection relative to control
Antinociceptive activity in Swiss albino mouse assessed as inhibition of acetic acid-induced abdominal constriction at 30 mg/kg, po administered 30 mins prior to testing measured for 10 mins starting 5 mins after acetic acid injection relative to control
Antinociceptive activity in Swiss albino mouse assessed as inhibition of acetic acid-induced abdominal constriction at 40 mg/kg, po administered 30 mins prior to testing measured for 10 mins starting 5 mins after acetic acid injection in presence of alpha-2 adrenergic receptor antagonist yohimbine
Antinociceptive activity against radiant heat-induced nociception in icv dosed CD1 mouse assessed as increase in tail withdrawal latency measured after 15 to 120 mins postdose by tail flick test
Antinociceptive activity against radiant heat-induced nociception in po dosed CD1 mouse assessed as increase in tail withdrawal latency measured after 15 to 120 mins postdose by tail flick test
Antinociceptive activity against radiant heat-induced nociception in po dosed CD1 mouse assessed as increase in tail withdrawal latency measured after 15 to 120 mins postdose by tail flick test in presence of 1 mg/kg, ip opioid receptor antagonist naloxone hydrochloride administered 30 mins before compound infusion
Antinociceptive activity against radiant heat-induced nociception in po dosed CD1 mouse assessed as increase in tail withdrawal latency measured after 15 to 120 mins postdose by tail flick test in presence of 50 mg/kg, ip GABAB receptor antagonist CGP-35348 administered 30 mins before compound infusion
Antinociceptive activity against radiant heat-induced nociception in po dosed CD1 mouse assessed as increase in tail withdrawal latency measured after 15 to 120 mins postdose by tail flick test in presence of 2 mg/kg, ip nicotinic receptor antagonist mecamylamine hydrochloride administered 30 mins before compound infusion
Antinociceptive activity against radiant heat-induced nociception in po dosed CD1 mouse assessed as increase in tail withdrawal latency measured after 15 to 120 mins postdose by tail flick test in presence of 2 mg/kg, ip alpha-2-adrenergic receptor antagonist yohimbine hydrochloride administered 30 mins before compound infusion
Antinociceptive activity against thermal nociception in po dosed CD1 mouse assessed as increase in latency period to elicit jumping or hind paw licking measured after 15 to 90 mins postdose by hot plate method
Antinociceptive activity against thermal nociception in po dosed CD1 mouse assessed as increase in latency period to elicit jumping or hind paw licking measured after 15 to 90 mins postdose by hot plate method in presence of 1 mg/kg, ip opioid receptor antagonist naloxone hydrochloride administered 30 mins before compound infusion
Antinociceptive activity against thermal nociception in po dosed CD1 mouse assessed as increase in latency period to elicit jumping or hind paw licking measured after 15 to 90 mins postdose by hot plate method in presence of 50 mg/kg, ip GABAB receptor antagonist CGP 35348 administered 30 mins before compound infusion
Antinociceptive activity against thermal nociception in po dosed CD1 mouse assessed as increase in latency period to elicit jumping or hind paw licking measured after 15 to 90 mins postdose by hot plate method in presence of 2 mg/kg, ip nicotinic receptor antagonist mecamylamine hydrochloride administered 30 mins before compound infusion
Antinociceptive activity against thermal nociception in po dosed CD1 mouse assessed as increase in latency period to elicit jumping or hind paw licking measured after 15 to 90 mins postdose by hot plate method in presence of 2 mg/kg, ip alpha-2-adrenergic receptor antagonist yohimbine hydrochloride administered 30 mins before compound infusion
Antinociceptive activity against radiant heat-induced nociception in CD1 mouse assessed as tail withdrawal latency at 1 mg/kg, po measured after 15 to 120 mins postdose by tail flick test
Antinociceptive activity against thermal nociception in po dosed CD1 mouse assessed as latency period to elicit jumping or hind paw licking at 1 mg/kg, po measured after 15 to 90 mins postdose by hot plate method
Antinociceptive activity against radiant heat-induced nociception in CD1 mouse assessed as tail withdrawal latency at 1 mg/kg, po measured after 15 to 120 mins postdose by tail flick test in presence of 0.1 to 1 mg/kg, ip alpha-1-adrenergic receptor antagonist prazosin administered 15 mins before compound infusion
Antinociceptive activity against thermal nociception in po dosed CD1 mouse assessed as latency period to elicit jumping or hind paw licking at 1 mg/kg, po measured after 15 to 90 mins postdose by hot plate method in presence of 0.1 to 1 mg/kg, ip alpha-1-adrenergic receptor antagonist prazosin administered 15 mins before compound infusion